Facing Sarcoma: Science, Loss, & the Power of Advocacy Podcast
Hosted by Upstate Medical University during Sarcoma Awareness Month, LFSA’s Kathy Higgins, Director of Education and Awareness, sat down with orthopedic
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR),
LFSA Co-Founder Debbie Soprano Honored by Boston Children’s Hospital
The Li-Fraumeni Syndrome Association (LFSA) is proud to announce that Co-Founder and Board Member Debbie Soprano has been recognized
Annual Whole-Body Imaging Contributes to Early Cancer Detection in Patients With Li-Fraumeni Syndrome
Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized cancers among
Seeking Participants for the INFORM Research Study
Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a first-of-its-kind blood
Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Published March 2025 by American Association for Cancer Research (AACR) is the updated version of the “Toronto Protocol,” the
Concerns about the consequences of cancer predisposition and relationships with quality of life in young adults with Li-Fraumeni syndrome
Researchers continue to study the psycho-social impact of Li-Fraumeni syndrome on young adults and their concerns about LFS, determining that effectively managing the challenges
Facing Sarcoma: Science, Loss, & the Power of Advocacy Podcast
Hosted by Upstate Medical University during Sarcoma Awareness Month, LFSA’s Kathy Higgins, Director of Education and Awareness,
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your thoughts about an upcoming clinical
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome
Immunotherapy has revolutionized the treatment of cancers in the last 15 years, demonstrating that a patient's very own immune system can seek and destroy a
New Study: Navigating Dating & Relationships with LFS
Northwestern University is conducting a groundbreaking study focused on understanding patient perspectives on dating and disclosure to romantic partners for males diagnosed with Li-Fraumeni
Additional cancer tumor types added to the Genetic Risk Assessment Guidelines
Breast, ovarian, pancreative, and prostate cancer have been added to the National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment Guidelines following a recent expansion that
Benefits of Liquid Biopsy
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in
Potential of Metformin and LFS
CancerNetwork, an arm of the prestigious journal Oncology, joined LFSA at the 7th International LFS Association Symposium to report on the latest advances in
